ArticleStem cell research & therapy2022

Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF/ERK pathway.

Tomoka Takao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.